Skip to main content
Fig. 3 | Renal Replacement Therapy

Fig. 3

From: Linagliptin inhibits lipopolysaccharide-stimulated interleukin-6 production, intranuclear p65 expression, and p38 mitogen-activated protein kinase phosphorylation in human umbilical vein endothelial cells

Fig. 3

Effects of linagliptin on p38 mitogen-activated protein kinase (MAPK) phosphorylation in lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs). HUVECs were treated with LPS and/or linagliptin. The phosphorylation of p38 MAPK in the cytosol fraction was determined by ELISA after 30 min of treatment. *P < 0.05 vs. control; ## P < 0.01 vs. LPS 1 μg/mL. Lina linagliptin

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us